Regeneron Pharmaceuticals (REGN) Stock Price, Quote, News & History | Benzinga

Regeneron Pharmaceuticals Inc (REGN) Stock Price, Quote, News & History

REGNNASDAQ

Trade with Public

Trade with Public

$826.64

-14.20-1.69%

At close: Aug 19, 5:00 PM EST

$826.64

-14.20-1.69%

Pre-Market: 4:00 AM EST

Dividend: The dividend Ex-Date was 3 days ago

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Dividends Compare Options Stock Report

Key Statistics

Open

-

Close

$826.64

Volume / Avg.

14.00 / 949.95K

Day Range

- - -

52 Wk Range

541.00 - 844.92

Market Cap

$85.11B

P/E Ratio

20.46

Dividend Yield

0.45%

Exchange

NASDAQ

RSI

68

Short Interest

3.48%

Days to Cover

3.94

Recent Regeneron Pharmaceuticals, Inc. News

Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug

Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven to reduce lesions in FOP patients.

Vandana Singh

Bill Ackman Donates $400 Million in Pershing Square Stock to Build a Research Institute After His Daughter’s Severe Brain Hemorrhage

Bill Ackman gifted $400 million of his Pershing Square stake to a brain research foundation after his daughter's near-fatal hemorrhage.

Radhika Anilkumar Nadig

European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent Indication

Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved clinical trial limitations.

Vandana Singh

Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'

China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s growing influence in medicine.

Mohd Haider

Sanofi Drops Dupixent Successor Candidate After Assessing Data

Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for regulatory filings.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

4.68B

Investing Cash Flow (TTM)

-704.20M

Financing Cash Flow (TTM)

-3.52B

Free Cash Flow (TTM)

3.58B

Capital Expenditure (TTM)

-1.11B

Net Change in Cash (TTM)

452.30M

Analyst Trends and Forecast

3

Mar

5

2

Apr

6

3

May

8

3

Jul

1

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.2

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$79.82B

PE Ratio (TTM)

20.46

PE Ratio (FWD)

17.61

PEG Ratio (TTM)

1.36

PS Ratio (TTM)

5.70

PB Ratio (TTM)

2.68

Earnings Yield % (TTM)

4.89%

Earnings Yield % (FWD)

5.68%

EV / EBITDA (TTM)

13.88

Price / EBITDA (TTM)

15.39

Price / Free Cash Flow (TTM)

24.75

Book Value / Share

$308.01

Company Debt

Total Debt

$1.99B

LT Debt

$1.99B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$2.46B

Debt to Equity

0.09

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$826.64

Volume / Avg.

14.00 / 949.95K

Day Range

- - -

52 Wk Range

541.00 - 844.92

Market Cap

$85.11B

P/E Ratio

20.46

Dividend Yield

0.45%

Exchange

NASDAQ

RSI

68

Short Interest

3.48%

Days to Cover

3.94

About

Sector

Health Care

Industry

Biotechnology

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Regeneron Pharmaceuticals (REGN) stock?

A

You can purchase shares of Regeneron Pharmaceuticals (NASDAQ:REGN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Regeneron Pharmaceuticals (REGN) competitors?

A

Other companies in Regeneron Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and argenx SE (NASDAQ:ARGX).

Q

What is the forecast, or price target, for Regeneron Pharmaceuticals (REGN) stock?

A

Regeneron Pharmaceuticals has a consensus price target of $796.61.

Q

What is the current price for Regeneron Pharmaceuticals (REGN)?

A

The stock price for Regeneron Pharmaceuticals (NASDAQ: REGN) is $826.64 last updated August 20, 2026 at 4:35 PM EDT.

Q

Does Regeneron Pharmaceuticals (REGN) pay a dividend?

A

There are no upcoming dividends for Regeneron Pharmaceuticals.

Q

When is Regeneron Pharmaceuticals (NASDAQ:REGN) reporting earnings?

A

Regeneron Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Regeneron Pharmaceuticals (REGN) going to split?

A

There is no upcoming split for Regeneron Pharmaceuticals.

Q

What sector and industry does Regeneron Pharmaceuticals (REGN) operate in?

A

Regeneron Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.